2020
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma
Changou CA, Shiah H, Chen L, Liu S, Luh F, Liu S, Cheng Y, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. The Oncologist 2020, 26: e367-e373. PMID: 33140457, PMCID: PMC7930412, DOI: 10.1002/onco.13582.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaMedian overall survivalProgression-free survivalHepatitis B virusHepatocellular carcinomaOverall survivalClinical outcomesClinical trialsSurvival rateMedian progression-free survivalPhase II clinical trialMultiple systemic therapiesPhase II safetySafety of capecitabineStable disease rateCommon adverse eventsDisease control rateAlpha-fetoprotein levelsBetter clinical outcomesTraditional Chinese medicine formulationEfficacy clinical trialsChinese medicine formulationCancer chemotherapeutic agentsCapecitabine combinationPrevious chemotherapy
2003
Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal Of Nuclear Cardiology 2003, 10: 132-139. PMID: 12673177, DOI: 10.1067/mnc.2003.7.Peer-Reviewed Original ResearchConceptsCongestive heart failureDoxorubicin therapyBaseline LVEFHeart failureCumulative doxorubicin doseLower baseline LVEFNormal baseline LVEFCancer-related deathCancer chemotherapeutic agentsLVEF monitoringLower LVEFDoxorubicin doseCardiac functionDoxorubicin chemotherapySerious toxicityLower incidenceEquilibrium radionuclideLVEFHigh incidenceERNA studiesAdditional casesChemotherapeutic agentsCancer typesPatientsTherapy
1985
Reduction of the drug-induced nephrotoxicity by ATP-MgCl2. 1. Effects on the cis-Diamminedichloroplatinum-treated isolated perfused kidneys
Sumpio B, Chaudry I, Baue A. Reduction of the drug-induced nephrotoxicity by ATP-MgCl2. 1. Effects on the cis-Diamminedichloroplatinum-treated isolated perfused kidneys. Journal Of Surgical Research 1985, 38: 429-437. PMID: 3872963, DOI: 10.1016/0022-4804(85)90058-7.Peer-Reviewed Original ResearchConceptsAcute renal failureATP-MgCl2Hr of perfusionCis-DiamminedichloroplatinumNephrotoxic effectsReabsorptive capacityCDDP treatmentRat kidneyATP-MgCl2 treatmentIsolated rat kidneyDrug-induced nephrotoxicityDirect nephrotoxic effectNew therapeutic modalitiesProximal tubule cellsCancer chemotherapeutic agentsCDDP therapyRenal failureMarked diuresisProtein reabsorptionTherapeutic modalitiesTubule cellsChemotherapeutic agentsMicrograms/KidneyMarked inhibition
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply